ReviewPyruvate kinase deficiency: The genotype-phenotype association
Introduction
Red cell pyruvate kinase (PK) deficiency, transmitted as an autosomal recessive trait, is the most frequent enzyme abnormality of the glycolytic pathway, and the most common cause of hereditary non spherocytic haemolytic anaemia together with class I glucose-6-phosphate dehydrogenase deficiency.1 Since the first detection in the early ’60 s,2 about 500 cases have been described, but many more remain unreported in the absence of unusual clinical or molecular features. The severity of haemolysis is highly variable, ranging from very mild or fully compensated forms to life-threatening neonatal anaemia necessitating exchange transfusions. PK deficiency has a world-wide geographical distribution, with an estimated prevalence of 1:20,000 in the general white population as assessed by gene frequency studies.3
Section snippets
Pyruvate kinase: structure and function
Pyruvate kinase (PK; ATP: pyruvate 2-o-phosphotransferase, EC 2.7.1.40) is a rate-controlling glycolytic enzyme that catalyses the irreversible conversion of phosphoenolpyruvate (PEP) to pyruvate, coupled to the synthesis of one molecule of ATP.4, 5The enzyme requires for its activity two equivalents of bivalent cations, usually Mg2+or Mn2+, and one equivalent of monovalent cations, usually K+.6, 7 The PK-catalysed reaction is the second ATP-generating step of
Gene and genetics
The PK-LR gene (over 9.5 kb) is located on chromosome 1q2115 where it directs tissue-specific transcription for both the liver-specific (LPK) and the red cell-specific (RPK) isoenzyme by the use of alternate promoters.28, 29 The codifying region is split into twelve exons, ten of which are shared by the two isoforms, while exons 1 and 2 are specific for the erythrocyte and the hepatic isoenzyme respectively.28, 30, 31
The cDNA encoding RPK is 2060 bp long and codes for 574 amino acids.31 In the
Clinical, haematological and diagnostic features of PK deficiency
Although abnormalities in PK-LR gene may result in alterations of both erythrocyte and liver enzyme, clinical symptoms are confined to red blood cells, the hepatic deficiency being usually compensated by the persistent enzyme synthesis in hepatocytes.47 Clinical manifestations of PK deficiency comprise the usual hallmarks of lifelong chronic haemolysis. The severity of clinical picture is variable, ranging from mild or fully compensated forms to life-threatening neonatal anaemia necessitating
The genotype-phenotype association
The biochemical and clinical consequences of PK mutations can be deduced from the investigation of the few homozygous patients and, to a lesser extent, from the study of larger series of compound heterozygotes grouped according to their clinical phenotype. More recently, the production and characterisation of the recombinant mutant proteins of human RPK made it possible to define the effects of amino acid replacements on the stability and kinetic properties of PK and helped to correlate
Clinical variability and phenotypic modifiers
Although in some cases there is a clear and direct correlation between the patient’s genotype and phenotype, caution is needed in predicting the clinical consequences of molecular abnormalities; in fact, the clinical manifestations of red cell enzyme defects reflect the complex interactions of physiological and environmental factors including genetic background, concomitant functional polymorphisms of other enzymes, posttranslational or epigenetic modifications, ineffective erythropoiesis and
References (88)
- et al.
Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population
Blood
(2000) - et al.
Amino acid effector binding to rabbit muscle pyruvate kinase
Arch Biochem Biophys
(1973) - et al.
The allosteric regulation of pyruvate kinase
J Biol Chem
(2000) - et al.
The role of potassium in muscle phosphorylations
J Biol Chem
(1942) - et al.
Evolution of glycolysis
Prog Biophys Mol Biol
(1993) - et al.
Regulation of pyruvate kinase M gene expression
Biochem Biophys Res Commun
(1999) - et al.
Pyruvate kinase type M2 and its role in tumor growth and spreading
Semin Cancer Biol
(2005) - et al.
The M1- and M2- type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing
J Biol Chem
(1986) - et al.
Crystal structure of Escherichia coli pyruvate kinase type I: molecular basis of the allosteric transition
Structure
(1995) - et al.
The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate
Structure
(1998)
The structure of pyruvate kinase from Leishmania mexicana reveals details of the allosteric transition and unusual effector specificity
J Mol Biol
Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia
J Biol Chem
Red cell pyruvate kinase (PK) deficiency: from genetics to clinical manifestations
Baillieres Best Pract Res Clin Haematol
Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia
Blood
A rapid purification method for human erythrocyte pyruvate kinase
Biochem Med
The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters
J Biol Chem
Structural analysis of human pyruvate kinase L-gene and identification of the promoter activity in erythroid cells
Biochem Biophys Res Commun
Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression
Blood
Disruption of a novel regulatory element in the erythroid-specific promoter of the human PKLR gene causes severe pyruvate kinase deficiency
Blood
Molecular analysis of 29 pyruvate kinase-deficient patients from central Europe with hereditary hemolytic anemia
Blood
Six previously undescribed pyruvate kinase mutations causing enzyme deficiency
Blood
Hereditary hemolytic anemia caused by diverse point mutations of pyruvate kinase gene found in Japan and Hong Kong
Blood
Molecular modelling of human red blood cell pyruvate kinase: structural implications of a novel G1091 to A mutation causing severe nonspherocytic hemolytic anemia
Blood
Pyruvate kinase deficiency in pregnancy complicated by iron overload
BJOG
Pyruvate kinase deficiency hemolytic anemia: two successful pregnancy outcomes
Am J Obstet Gynecol
Molecular basis of impaired pyruvate kinase isozyme conversion in erythroid cells: a single amino acid substitution near the active site and decreased mRNA content of the R-type PK
Biochem Biophys Res Commun
Mutations in the pyruvate kinase L gene in patients with hereditary hemolytic anemia
Blood
Frame shift mutation, exon skipping, and a two-codon deletion caused by splice site mutations account for pyruvate kinase deficiency
Blood
Molecular characterization of PK-LR gene in pyruvate kinase deficient patients
Blood
Point mutations in the L-type pyruvate kinase gene of two children with hemolytic anemia caused by pyruvate kinase deficiency
Blood
Identical point mutations of the R-type pyruvate kinase (PK) cDNA found in unrelated PK variants associated with hereditary hemolytic anemia
Blood
Ineffective erythropoiesis in mutant mice with deficient pyruvate kinase activity
Exp Hematol
Iron status and HFE genotype in erythrocyte pyruvate kinase deficiency: study of Italian cases
Blood Cells Mol Dis
Heterogeneity of hemochromatosis in Italy
Gastroenterology
Hereditary hemolytic anemias due to enzyme disorders
A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital non-spherocytic hemolytic anemia
Trans Assoc Am Physicians
Dual divalent cation requirement for activation of pyruvate kinase: essential roles of both enzyme- and nucleotide-bound metal ions
Biochemistry
Pyruvate kinase: current status of regulatory and functional properties
Comp Biochem Physiol B Biochem Mol Biol
Isozymes of pyruvate kinase in vertebrates: their physical, chemical, kinetic and immunological properties
Int J Biochem
Change of pyruvate kinase isozymes from M2- to L-type during development of the red cell
Br J Haematol
The human liver-type pyruvate kinase (PKL) gene is on chromosome 1 at band q21
Cytogenet Cell Genet
Pyruvate kinase: activation by and catalytic role of the monovalent and divalent cations
Mol Cell Biochem
The structure of cat muscle pyruvate kinase
EMBO J
Structure of rabbit muscle pyruvate kinase complexed with Mn2+, K+, and pyruvate
Biochemistry
Cited by (118)
Updates and advances in pyruvate kinase deficiency
2023, Trends in Molecular MedicineClinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency
2021, Molecular Therapy Methods and Clinical DevelopmentCitation Excerpt :This approach allows the restoration of the specific gene functionality without compromising the endogenous regulatory control of the gene expression. In the case of PKD, this strategy would be applicable to most PKD patients, with the exception of those carrying mutations in the promoter or regulatory regions (only 1.1% of the identified7). Here, we have addressed the development of a CRISPR/Cas9 + donor AAV6 delivery strategy to knock in a healthy version of the RPK gene at the PKLR locus to correct PKD.
Consensus document for the diagnosis and treatment of pyruvate kinase deficiency
2021, Medicina ClinicaSix novel variants in the PKLR gene associated with pyruvate kinase deficiency in Argentinian patients
2021, Clinical BiochemistryCitation Excerpt :We were able to redefine her previous diagnosis on account of the molecular study of the PKLR gene, which highlights the difficulties in the differential diagnosis between CDA and PKD in absence of PK enzyme assay. The proband had two missense variants in the PKLR gene, one of which (Arg486Trp) is described to have a high frequency in Southern Europe and is associated at the homozygote state with a “mild phenotype” [22]. The other, not previously described variant (Asp221His) would be responsible for the impossibility of oligomerization of the tetramer according to the results of molecular modeling.
New drug approvals for 2022: Synthesis and clinical applications
2023, Medicinal Research Reviews
- 1
Tel.: +39 382 987227; fax: +39 382 423108.